Consider a cancer medicine built to find a particular target. The medicine may be beautifully designed. The target may even have a familiar name. But the practical question is awkward: what is the patient’s tumor expressing today? A tissue sample taken earlier can tell a researcher something valuable about the past. Treatment can change the biology in the meantime. Precede Biosciences has built its business around making that moving picture easier to see.
- The input: 1 mL of plasma, carrying cell-free DNA and its regulatory clues.
- The customer: researchers developing medicines and investigating response, resistance and patient selection.
- The distinction: inferred gene activity, with Insight supplied for research use.
The target may have moved
Mutation-focused liquid biopsies helped make precision oncology practical. A blood sample could reveal a DNA alteration that pointed toward a medicine. Yet many newer therapies raise a different question. An antibody-drug conjugate, for instance, delivers its payload through a target on a cell. Researchers want to understand target expression, the pathways sustaining the cancer and the ways those pathways change under pressure.
Precede occupies that space between molecular profiling and therapeutic development. Tissue immunohistochemistry, RNA sequencing and imaging remain useful alternatives for particular questions. FoundationOne Liquid CDx, meanwhile, offers an approved genomic blood test. Precede’s research proposition is to add functional information from plasma. An investigator deciding how to study a medicine needs to know which kind of information will answer the question.
A clue that survived the cell
The scientific trick begins with material released by cells. DNA arrives in blood with epigenomic features that carry information about gene regulation. Precede profiles active promoters, active enhancers and DNA methylation, then applies computational methods to infer expression and pathway activity. The assay measures regulatory evidence in cell-free DNA. Its expression readouts are inferred, rather than obtained by directly sequencing RNA.
A useful detail in the foundational Nature Medicine study explains why several signals matter. Promoter activity at the gene encoding the estrogen receptor distinguished receptor status only modestly. Enhancer activity gave a stronger distinction. Reading a single regulatory clue could miss something that another clue made visible. The proof-of-concept work examined 433 people across 15 cancers; it established a research foundation, rather than a universal clinical test.
The company’s scientific co-founders, Sylvan Baca, Matthew Freedman and Toni Choueiri, came from Dana-Farber Cancer Institute. Rehan Verjee became its founding chief executive after senior roles at Merck KGaA. Precede formed in 2021 through 5AM Ventures’ 4:59 Initiative. The combination joined people studying cancer’s mechanisms with an executive accustomed to decisions about developing and selling medicines.
For the laboratory, the small input conceals a large measurement job. Insight’s product sheet describes approximately 100 million gene-regulation datapoints sequenced. It separates transcriptional activation relative to a healthy baseline from tumor-specific expression estimates. Those outputs answer related questions, but treating them as one interchangeable number would throw away useful distinctions.
Presence is not dependence
Breast cancer supplies a revealing example. Knowing that a cancer expresses the estrogen receptor is useful. Knowing how much its growth depends on the receptor’s pathway asks a further question. Precede’s research index, PERDI, was designed to examine ER-dependent and ER-independent mechanisms. Its December 2024 presentation described the approach; subsequent studies examined associations with endocrine-therapy response.
In prostate cancer, the company studied plasma-based PSMA expression and its relationship to PSMA-PET imaging. At ASCO 2025, collaborators reported pathways associated with outcomes following radioligand treatment. These examples show the attraction for a drug developer: a target can be present while other biology helps explain why a patient responds poorly. A richer measurement gives researchers another hypothesis to investigate.
The same logic extends to a cancer’s identity. At ESMO 2025, Precede presented small-cell lung-cancer research assessing targets including DLL3, SEZ6 and CEACAM5 alongside molecular subtypes. Sorting patients by functional biology could help researchers design studies around differences that a broad disease label leaves hidden.
A business inside the clinical trial
Precede Bio Insight launched under that name in April 2026. It offers genome-wide transcriptional profiling through research collaborations, with serial samples allowing teams to study change across treatment. Launch studies involved Dana-Farber, Genentech, Emory and Fred Hutchinson. The company also describes Precede Bio Dx as an offering for patient selection in clinical trials. Insight itself remains a research-use-only product.
The business model follows the scientist’s workflow. Biopharmaceutical teams bring development questions and samples; Precede supplies assay and analytical capabilities. Academic collaborations build evidence around particular diseases and targets. Working within drug development creates opportunities to learn which readouts matter before a proposed diagnostic reaches routine care.
“More is not always better.”
Rehan Verjee, January 2025 DeciBio interview
In that interview, Verjee emphasized a focused route through biopharma trials toward clinical practice. The discipline is appealing: a platform may generate abundant data, but its commercial value depends on helping someone make a consequential decision. Precede’s stated culture stresses trust and care among colleagues. Its scientific work requires another kind of trust: agreement between an inferred signal and an independently measured biological fact.
The cost of making a signal useful
The capital commitment is substantial. Precede emerged from stealth in October 2023 with $57 million in combined backing. In its January 2026 financing announcement, it reported $63.5 million of Series B equity and a $20 million credit facility. The latter is financing capacity, not another equity round. The company said the funds would support scaling as demand from medicine developers increased.
New backers included Labcorp Venture Fund and UPMC Enterprises, bringing diagnostics and health-system perspectives into the investor group. Commercial expansion therefore has two linked tasks: serve the research customer at greater scale and develop evidence for diagnostic applications. A useful assay needs a workable route through both the laboratory and the organization buying it.
$63.5MSeries B equity
$20MCredit facility
For researchers, practical limits belong in the study design. Insight’s product sheet specifies different tumor-fraction thresholds for different readouts and uses indication-specific algorithms for tumor expression. Weak tumor signals can constrain interpretation. Evidence in advanced cancer also does not automatically establish performance in screening or another disease. Exploratory multiple-sclerosis work is an invitation to investigate, not a clinical diagnosis.
At ASCO in May 2026, Precede presented MET-related lung-cancer research involving tepotinib and progression on osimertinib. The transferable lesson is straightforward: collect biological context while treatment is happening, connect it to outcomes and validate the proposed use. A tumor’s habits can change. The business opportunity lies in making those changes legible soon enough for researchers to act.